On Tuesday, President Trump sent a budget request to Congress. The request included a $5 million budget request for the FDA in order to act upon CBD initiatives.
In the request, the FDA indicates that the new funding will enable it to continue regulating the usage of cannabis-derived substances, such as CBD, in FDA-regulated products. The request reads, in part:
FDA requests a total of $5 million across ORA ($2.0M), CFSAN ($2.0M), FDA HQ ($0.5M),
and CVM ($0.5M). This new funding will enable FDA to continue regulating the usage of
cannabis-derived substances, such as cannabidiol (CBD), in FDA-regulated products such as
dietary supplements and when used as unapproved food and feed additives. The initiative will
support regulatory activities, including developing policy, and continue to perform its existing
regulatory responsibilities including review of product applications, inspections, enforcement,
and targeted research.
It appears that some individuals in the industry are cautiously in favor of the move. Loren Israelsen, president of the United Natural Products Alliance, stated in a NutraIngredients report that the new funding would permit the FDA to start inspecting many facilities that have appeared to service the new market. Further, some of the facilities manufacture full-spectrum hemp, while others offer finished goods. Israelsen also added that,
“We have urged the FDA to be far more active in inspecting facilities. We believe they have the authority to do so.”
Daniel Fabricant, President and CEO of Natural Products Association, also shared in the aforementioned report that the new funding is welcome, but that it also puts the cart before the horse. The Natural Products Association advocates that the first thing that the FDA should do is to establish safe exposure levels for CBD, and such levels would take into account the many sources of molecules that consumes have available to them, including supplements, beverages, and food.